Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria
about
Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspectiveSuppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureusIn vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model.Activity of and resistance to moxifloxacin in Staphylococcus aureus.Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones.Is selection relevant in the evolutionary emergence of drug resistance?The changing face of antibiotic prescribing: the mutant selection window.Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis.Mutant selection window hypothesis updated.Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones.Quinolone-mediated bacterial death.Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.Drug interactions modulate the potential for evolution of resistance.Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.Quinolones: action and resistance updated.Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining regionEnhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.Pseudomonas Endocarditis with an unstable phenotype: the challenges of isolate characterization and Carbapenem stewardship with a partial review of the literature.Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections.Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis.Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis.Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.Low correlation between MIC and mutant prevention concentration.Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.In vitro potency and efficacy favor later generation fluoroquinolones for treatment of canine and feline Escherichia coli uropathogens in the United States.Synergistic combination of two antimicrobial agents closing each other's mutant selection windows to prevent antimicrobial resistance.Bifidobacterium adolescentis is intrinsically resistant to antitubercular drugs
P2860
Q24535810-ED15B05A-4516-4B3B-9DCC-7E9CF0B0D535Q26771850-83A33067-8666-4DE7-AD4B-242E0F3914B4Q33556083-C3A52F39-311D-4038-BCF1-C2B66806F90FQ33983092-B0EADA6C-6895-4F4C-A4B3-6FCC269554B0Q34352260-62A5782C-993F-4264-9D4E-630D7774FC84Q34788573-E94D2C3C-FEAD-44D7-839E-72ADF97B42EFQ34885313-39BDD5ED-C3DE-44BD-973D-DF3FD42E29F5Q35140423-05729412-2A43-48F0-9A49-374CD6DEEE90Q35215435-1D2E3031-E799-4A66-99B5-DDAB81BBEF85Q35826386-CEC1DE52-384B-42B9-8C6E-61176677A238Q35875929-5937BD52-C63B-4997-8933-1EDF8DB9FA78Q36607637-F10BEC3D-44E2-444C-B039-3F72C021C04CQ36728061-BB7D65CD-6650-4376-A14F-97A84B290ECDQ36817994-1C8B66DF-F357-4A07-BAFD-D20A50465A54Q36921143-CF0497B0-67C5-4193-9AD1-666745068A39Q36933441-BF65195A-037D-4D2F-93BD-E96C22CDBF2CQ36937085-533CAA73-689B-485C-9E89-A0A1D804A355Q37568953-978E3591-66C9-4A0B-8730-DFAB7B96B6C3Q37595559-C1FB0EB9-EBFF-4ECE-99F6-87F501C3CCF5Q39478070-C093952D-400E-42AC-88A6-7F7F4100DBC9Q39478440-1F2FBAF5-1C81-4DA7-A0C7-E84BE317CFE7Q39731893-A2DE67D0-1233-47EE-B692-CFBB16659F46Q40073768-5A9FE2C5-FC9E-4D2B-A8E7-248E8C38298EQ40631566-13DAC2AF-7DAF-41E1-9B60-831744F3BF42Q41901445-03271009-4D2F-4DA7-BE5B-D7AECF88D7F5Q42062555-99E31B89-FA90-4AB6-9431-8359469A62AFQ42708766-46EC1A86-853E-441A-BB76-20592F0D2F0BQ42727166-B02A16E8-28B0-49BA-97F9-4124A5359F86Q42784827-454A98D0-AD2E-45D0-9EFD-F42F9AD3F742Q42943040-42C33872-6115-42BF-9EB1-1F7A54050234Q43251107-9FD1C420-EB37-4804-AC95-5226637DE8B0Q44755434-9D403DFA-BDB7-411C-9C50-9B2C2F6A74DBQ53685683-DF777F0A-E9D1-448F-8661-4F28E26B7533Q58793869-65E89079-657F-4B68-8300-CF37EE45C147
P2860
Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Mutant prevention concentratio ...... e potency against mycobacteria
@ast
Mutant prevention concentratio ...... e potency against mycobacteria
@en
Mutant prevention concentratio ...... e potency against mycobacteria
@nl
type
label
Mutant prevention concentratio ...... e potency against mycobacteria
@ast
Mutant prevention concentratio ...... e potency against mycobacteria
@en
Mutant prevention concentratio ...... e potency against mycobacteria
@nl
prefLabel
Mutant prevention concentratio ...... e potency against mycobacteria
@ast
Mutant prevention concentratio ...... e potency against mycobacteria
@en
Mutant prevention concentratio ...... e potency against mycobacteria
@nl
P2093
P2860
P1476
Mutant prevention concentratio ...... e potency against mycobacteria
@en
P2093
G Sindelar
J Domagala
P2860
P304
P356
10.1128/AAC.44.12.3337-3343.2000
P407
P577
2000-12-01T00:00:00Z